Document:

Exhibit
4.1

 

NEITHER
THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON
STOCK PURCHASE WARRANT

DATA443
RISK MITIGATION, INC.

 

Warrant
Shares: 100,000,000

Date
of Issuance: December 10, 2020 (the “Issuance Date”)

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received (in connection with the funding
of that common stock purchase agreement dated December 10, 2020, between the Company (as defined below) and the Investor (as defined
below)) (the “CSPA”), TRITON FUNDS, LP, a Delaware limited partnership (the “Investor” and
including any permitted and registered assigns), is entitled, upon the terms and subject to the limitations on exercise and the
conditions hereinafter set forth, at any time during the Exercise Period, to purchase from DATA443 RISK MITIGATION, INC., a Nevada
corporation (the “Company”), up to 100,000,000 shares of Common Stock (as defined below) (the “Warrant
Shares”) at the Exercise Price per share then in effect. The number of Warrant Shares for which this Warrant may be
exercised is subject to adjustment in accordance with the terms hereof. This Warrant is issued by the Company as of the date hereof
pursuant to the CSPA.

 

Capitalized
terms used in this Warrant shall have the meanings set forth in the CSPA unless otherwise defined in the body of this Warrant
or in Section 14 below. For purposes of this Warrant, the term “Exercise Price” shall mean $0.01 per
share, subject to adjustment as provided herein (including but not limited to cashless exercise), and the term “Exercise
Period” shall mean the period commencing on the Issuance Date and ending on 5:00 p.m. eastern standard time on the five-year
anniversary of such date. In the event that the S-1 Registration Statement registering the resales of the Warrant Shares is not
deemed effective within ninety (90) days of the Issuance Date, one hundred million (80,000,000) Warrants shall terminate and twenty
million (20,000,000) Warrants shall remain (the “Cashless Warrant Shares”) which shall either be registered by the
Company in an S-1 Registration Statement or shall be available for cashless exercise pursuant to the terms herein.

 

    	1

     

    

 

1.
EXERCISE OF WARRANT.

 

(a)
Mechanics of Exercise. Subject to the terms and conditions hereof, the rights represented by this Warrant may be exercised in
whole or in part at any time or times during the Exercise Period by delivery of a written notice, in the form attached hereto
as Exhibit A (the “Exercise Notice”), of the Investor’s election to exercise this Warrant. The
Investor shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Partial exercises of
this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect
of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant
Shares purchased. On or before the second Trading Day (the “Warrant Share Delivery Date”) following the date
on which the Company shall have received the Exercise Notice, which Exercise Notice must be received by the Company prior to 11
a.m., New York, New York time to count as received on such date, and upon receipt by the Company of payment to the Company of
an amount equal to the applicable Exercise Price multiplied by the number of Warrant Shares as to which all or a portion of this
Warrant is being exercised (the “Aggregate Exercise Price” and together with the Exercise Notice, the “Exercise
Delivery Documents”) in cash or by wire transfer of immediately available funds (or by cashless exercise if permitted
under the terms of this Warrant, in which case there shall be no Aggregate Exercise Price provided), the Company shall (or direct
its transfer agent to) issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate,
registered in the Company’s share register in the name of the Investor or its designee, for the number of shares of Common
Stock to which the Investor is entitled pursuant to such exercise. Upon delivery of the Exercise Delivery Documents, the Investor
shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this
Warrant has been exercised, irrespective of the date of delivery of the certificates evidencing such Warrant Shares. If this Warrant
is submitted in connection with any exercise and the number of Warrant Shares represented by this Warrant is greater than the
number of Warrant Shares being acquired upon an exercise, then the Company shall as soon as practicable and in no event later
than three business days after any exercise and at its own expense, issue a new Warrant (in accordance with Section 6)
representing the right to purchase the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant,
less the number of Warrant Shares with respect to which this Warrant is exercised.

 

If
the Company fails to cause its transfer agent to transmit to the Investor the respective shares of Common Stock by the respective
Warrant Share Delivery Date, then the Investor will have the right to rescind such exercise in Investor’s sole discretion,
and such failure shall be deemed an “Event of Default” under the CSPA. Without in any way limiting the Investor’s
right to pursue other remedies, including actual damages and/or equitable relief, the parties agree that if delivery of the Common
Stock issuable upon conversion of this Warrant is not delivered by the Warrant Share Delivery Date the Company shall pay to the
Investor $3,000 per day, for each day beyond the Warrant Share Delivery Date that the Company fails to deliver such Common Stock
(unless such failure results from war, acts of terrorism, an epidemic, or natural disaster). Such amount shall be paid to Investor
in cash by the fifth day of the month following the month in which it has accrued. The Company agrees that the right to exercise
is a valuable right to the Investor. The damages resulting from a failure, attempt to frustrate, interference with such exercise
right are difficult if not impossible to qualify. Accordingly, the parties acknowledge that the liquidated damages provision contained
in this Section 1(a) are justified.

 

    	2

     

    

 

The
Cashless Warrant Shares may be exercised on a cashless basis only after and upon the failure of the Company to have an S-1 Registration
Statement registering the Warrant Shares declared effective by the SEC within ninety (90) days from the date hereof. If, at any
time from the effectiveness of the S-1 Registration Statement through the end of the Exercise Period or after ninety (90) days
from the date hereof, there is no effective registration statement of the Company covering the Investor’s immediate resale
of the Warrant Shares without any limitations, then the Investor may elect to receive the Cashless Warrant Shares pursuant to
a cashless exercise, in lieu of a cash exercise, equal to the value of this Warrant determined in the manner described below (or
of any portion thereof remaining unexercised) by surrender of this Warrant and a Notice of Exercise, in which event the Company
shall issue to Investor a number of Common Stock computed using the following formula:

 

X
= Y (A-B)

A

 

	Where
    	 	X =	the number of Shares to be
    issued to Investor.
	 	 	 	 
	 	 	Y =	the number of Warrant Shares that the Investor
    elects to purchase under this Warrant (at the date of such calculation).
	 	 	 	 
	 	 	A =	the Market Price (at the date of such calculation).
	 	 	 	 
	 	 	B =	Exercise Price (as adjusted to the date of such
    calculation).

 

(b)
No Fractional Shares. No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment
pursuant hereto. All Warrant Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes
of determining whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise
would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay to the
Investor otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then-current fair
market value of a Warrant Share by such fraction.

 

(c)
Investor’s Exercise Limitations. The Company shall not affect any exercise of this Warrant, and the Investor shall not have
the right to exercise any portion of this Warrant, to the extent that after giving effect to issuance of Warrant Shares upon exercise
as set forth on the applicable Notice of Exercise, the Investor (together with the Investor’s Affiliates (as such term is
defined under the Exchange Act), and any other persons acting as a group together with the Investor or any of the Investor’s
Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation, as defined below. For purposes of the foregoing
sentence, the number of shares of Common Stock beneficially owned by the Investor and its Affiliates shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall
exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, non-exercised portion
of this Warrant beneficially owned by the Investor or any of its Affiliates and (ii) exercise or conversion of the unexercised
or non-converted portion of any other securities of the Company (including without limitation any other Common Stock Equivalents)
subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Investor
or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this paragraph (d), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act, it being acknowledged by the Investor that the Company
is not representing to the Investor that such calculation is in compliance with Section 13(d) of the Exchange Act and the Investor
is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained
in this paragraph applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by
the Investor together with any affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion
of the Investor, and the submission of a Notice of Exercise shall be deemed to be the Investor’s determination of whether
this Warrant is exercisable (in relation to other securities owned by the Investor together with any Affiliates) and of which
portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have
no obligation to verify or confirm the accuracy of such determination.

 

    	3

     

    

 

For
purposes of this Section 1(c), in determining the number of outstanding shares of Common Stock, the Investor may rely on
the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written
notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the request of
the Investor, the Company shall within two Trading Days confirm to the Investor the number of shares of Common Stock then outstanding.
In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise
of securities of the Company, including this Warrant, by the Investor or its affiliates since the date as of which such number
of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of
the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. The limitations contained in this paragraph shall apply to a successor Investor of this
Warrant.

 

2.
ADJUSTMENTS. The Exercise Price and the number of Warrant Shares shall be adjusted from time to time as follows:

 

(a)
Distribution of Assets. If the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire
its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including without limitation any distribution
of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement
or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in
each such case:

 

(i)
any Exercise Price in effect immediately prior to the close of business on the record date fixed for the determination of holders
of shares of Common Stock entitled to receive the Distribution shall be reduced, effective as of the close of business on such
record date, to a price determined by multiplying such Exercise Price by a fraction (i) the numerator of which shall be the Closing
Sale Price of the shares of Common Stock on the Trading Day immediately preceding such record date minus the value of the Distribution
(as determined in good faith by the Company’s Board of Directors) applicable to one share of Common Stock, and (ii) the
denominator of which shall be the Closing Sale Price of the shares of Common Stock on the Trading Day immediately preceding such
record date; and

 

    	4

     

    

 

(ii)
the number of Warrant Shares shall be increased to a number of shares equal to the number of shares of Common Stock obtainable
immediately prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock
entitled to receive the Distribution multiplied by the reciprocal of the fraction set forth in the immediately preceding clause
(i); provided, however, that in the event that the Distribution is of shares of common stock of a company (other than the Company)
whose common stock is traded on a national securities exchange or a national automated quotation system (“Other Shares
of Common Stock”), then the Investor may elect to receive a warrant to purchase Other Shares of Common Stock in lieu
of an increase in the number of Warrant Shares, the terms of which shall be identical to those of this Warrant, except that such
warrant shall be exercisable into the number of shares of Other Shares of Common Stock that would have been payable to the Investor
pursuant to the Distribution had the Investor exercised this Warrant immediately prior to such record date and with an aggregate
exercise price equal to the product of the amount by which the exercise price of this Warrant was decreased with respect to the
Distribution pursuant to the terms of the immediately preceding clause (i) and the number of Warrant Shares calculated in accordance
with the first part of this clause (ii).

 

(b)
Stock Splits. If the Company, at any time while this Warrant is outstanding: (i) subdivides outstanding shares of Common Stock
into a larger number of shares, or (ii) combines (including by way of reverse stock split) outstanding shares of Common Stock
into a smaller number of shares, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator
shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and
of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number
of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section 2(b) shall become effective immediately after
the effective date in the case of a subdivision or combination.

 

3.
FUNDAMENTAL TRANSACTIONS. If, at any time while this Warrant is outstanding, (i) the Company effects any merger of the
Company with or into another entity and the Company is not the surviving entity (such surviving entity, the “Successor
Entity”), (ii) the Company effects any sale of all or substantially all of its assets in one or a series of related
transactions, (iii) any tender offer or exchange offer (whether by the Company or by another individual or entity, and approved
by the Company) is completed pursuant to which holders of Common Stock are permitted to tender or exchange their shares of Common
Stock for other securities, cash or property and the holders of at least 50% of the Common Stock accept such offer, or (iv) the
Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination
of shares of Common Stock) (in any such case, a “Fundamental Transaction”), then, upon any subsequent exercise
of this Warrant, the Investor shall have the right to receive the number of shares of Common Stock of the Successor Entity or
of the Company and any additional consideration (the “Alternate Consideration”) receivable upon or as a result
of such reorganization, reclassification, merger, consolidation or disposition of assets by a holder of the number of shares of
Common Stock for which this Warrant is exercisable immediately prior to such event (disregarding any limitation on exercise contained
herein solely for the purpose of such determination). For purposes of any such exercise, the determination of the Exercise Price
shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable
in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among
the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate
Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental
Transaction, then the Investor shall be given the same choice as to the Alternate Consideration it receives upon any exercise
of this Warrant following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any Successor
Entity in such Fundamental Transaction shall issue to the Investor a new warrant consistent with the foregoing provisions and
evidencing the Investor’s right to exercise such warrant into Alternate Consideration.

 

    	5

     

    

 

4.
NON-CIRCUMVENTION. The Company covenants and agrees that it will not, by amendment of its certificate of incorporation,
bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or
sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of
this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required
to protect the rights of the Investor. Without limiting the generality of the foregoing, the Company (i) shall not increase the
par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect,
(ii) shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully
paid and non-assessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, for so long as this Warrant
is outstanding, have authorized and reserved, free from preemptive rights, three times the number of shares of Common Stock issuable
under the Warrant, or as otherwise required under the CSPA, to provide for the exercise of the rights represented by this Warrant
(without regard to any limitations on exercise).

 

5.
WARRANT HOLDER NOT DEEMED A STOCKHOLDER. Except as otherwise specifically provided herein, this Warrant, in and of itself,
shall not entitle the Investor to any voting rights or other rights as a stockholder of the Company. In addition, nothing contained
in this Warrant shall be construed as imposing any liabilities on the Investor to purchase any securities (upon exercise of this
Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors
of the Company.

 

6.
REISSUANCE.

 

(a)
Lost, Stolen or Mutilated Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company will, on such terms as
to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender
thereof), issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed.

 

    	6

     

    

 

(b)
Issuance of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such
new Warrant shall be of like tenor with this Warrant, and shall have an issuance date, as indicated on the face of such new Warrant
which is the same as the Issuance Date.

 

7.
TRANSFER.

 

(a)
Notice of Transfer. The Investor agrees to give written notice to the Company before transferring this Warrant or transferring
any Warrant Shares of such Investor’s intention to do so, describing briefly the manner of any proposed transfer. Promptly
upon receiving such written notice, the Company shall present copies thereof to the Company’s counsel. If the proposed transfer
may be effected without registration or qualification (under any federal or state securities laws), the Company, as promptly as
practicable, shall notify the Investor thereof, whereupon the Investor shall be entitled to transfer this Warrant or to dispose
of Warrant Shares received upon the previous exercise of this Warrant, all in accordance with the terms of the notice delivered
by the Investor to the Company; provided, however, that an appropriate legend may be endorsed on this Warrant or the certificates
for such Warrant Shares respecting restrictions upon transfer thereof necessary or advisable in the opinion of counsel and satisfactory
to the Company to prevent further transfers which would be in violation of Section 5 of the Securities Act and applicable state
securities laws; and provided further that the prospective transferee or purchaser shall execute the Assignment of Warrant attached
hereto as Exhibit B and such other documents and make such representations, warranties, and agreements as may be required
solely to comply with the exemptions relied upon by the Company for the transfer or disposition of the Warrant or Warrant Shares.

 

(b)
If the proposed transfer or disposition of this Warrant or such Warrant Shares described in the written notice given pursuant
to this Section 7 may not be effected without registration or qualification of this Warrant or such Warrant Shares, the
Investor will limit its activities in respect to such transfer or disposition as are permitted by law.

 

(c)
Any transferee of all or a portion of this Warrant shall succeed to the rights and benefits of the initial Investor of this Warrant
under the CSPA (registration rights, expenses, and indemnity).

 

8.
NOTICES. Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall
be given in accordance with the notice provisions contained in the CSPA. The Company shall provide the Investor with prompt written
notice (i) immediately upon any adjustment of the Exercise Price, setting forth in reasonable detail, the calculation of such
adjustment and (ii) at least 20 days prior to the date on which the Company closes its books or takes a record (A) with respect
to any dividend or distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of any stock
or other securities directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock or other
property, pro rata to the holders of shares of Common Stock or (C) for determining rights to vote with respect to any Fundamental
Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public prior to
or in conjunction with such notice being provided to the Investor.

 

    	7

     

    

 

9.
AMENDMENT AND WAIVER. The terms of this Warrant may be amended or waived (either generally or in a particular instance
and either retroactively or prospectively) only with the written consent of the Company and the Investor.

 

10.
Governing Law. This Warrant shall be governed by and interpreted in accordance with the laws of the State of Nevada without
regard to the principles of conflicts of law (whether of the State of Nevada or any other jurisdiction).

 

11.
Arbitration. Any disputes, claims, or controversies arising out of or relating to this Warrant, or the transactions, contemplated
thereby, or the breach, termination, enforcement, interpretation, or validity thereof, including the determination of the scope
or applicability of this Warrant to arbitrate, shall be referred to and resolved solely and exclusively by binding arbitration
to be conducted before the Judicial Arbitration and Mediation Service (“JAMS”), or its successor pursuant the
expedited procedures set forth in the JAMS Comprehensive Arbitration Rules and Procedures (the “Rules”), including
Rules 16.1 and 16.2 of those Rules. The arbitration shall be held in Los Angeles, California, before a tribunal consisting of
three (3) arbitrators each of whom will be selected in accordance with the “strike and rank” methodology set forth
in Rule 15. Either party to this Warrant may, without waiving any remedy under this Warrant, seek from any federal or state court
sitting in the State of California any interim or provisional relief that is necessary to protect the rights or property of that
party, pending the establishment of the arbitral tribunal. The costs and expenses of such arbitration shall be paid by and be
the sole responsibility of the Company, including but not limited to the Investor’s attorneys’ fees and each arbitrator’s
fees. The arbitrators’ decision must set forth a reasoned basis for any award of damages or finding of liability. The arbitrators’
decision and award will be made and delivered as soon as reasonably possible and in any case within sixty (60) days’ following
the conclusion of the arbitration hearing and shall be final and binding on the parties and may be entered by any court having
jurisdiction thereof.

 

12.
JURY TRIAL WAIVER. THE COMPANY AND THE INVESTOR HEREBY WAIVE A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM
BROUGHT BY EITHER OF THE PARTIES HERETO AGAINST THE OTHER IN RESPECT OF ANY MATTER ARISING OUT OF OR IN CONNECTION WITH THIS WARRANT.

 

13.
ACCEPTANCE. Receipt of this Warrant by the Investor shall constitute acceptance of and agreement to all of the terms and
conditions contained herein.

 

14.
CERTAIN DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:

 

(a)
“Closing Sale Price” means, for any security as of any date, (i) the last closing trade price for such security
on the Trading Market, as reported by the Trading Market, or, if the Trading Market begins to operate on an extended hours basis
and does not designate the closing trade price, then the last trade price of such security prior to 4:00 p.m., New York time,
as reported by the Trading Market, or (ii) if the foregoing does not apply, the last trade price of such security in the over-the-counter
market for such security as reported by the Trading Market, or (iii) if no last trade price is reported for such security by the
Trading Market, the average of the bid and ask prices of any market makers for such security as reported by the Trading Market.
If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing
Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Investor.
All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction
during the applicable calculation period.

 

    	8

     

    

 

(b)
“Common Stock” means the Company’s common stock, par value $0.00001 per share, and any other class of
securities into which such securities may hereafter be reclassified or changed.

 

(c)
“Common Stock Equivalents” means any securities of the Company that would entitle the holder thereof to acquire
at any time Common Stock, including without limitation any debt, preferred stock, rights, options, warrants or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.

 

(d)
“Market Price” means the highest traded price of the Common Stock during the thirty (30) Trading Days prior
to the date of the respective Exercise Notice.

 

(e)
“OTC Markets” means OTCQX, OTCQB, OTC Pink, the OTC Bulletin Board.

 

(f)
“Trading Day” means (i) any day on which the Common Stock is listed or quoted and traded on its Trading Market,
(ii) if the Common Stock is not then listed or quoted and traded on any national securities exchange, then a day on which trading
occurs on any over-the-counter markets, or (iii) if trading does not occur on the over-the-counter markets, any business day.

 

(g)
“Trading Market” means the OTC Markets or any equivalent principal securities exchange or other securities
market on which the Common Stock is being traded or quoted.

 

15.
PIGGYBACK REGISTRATION RIGHTS. The Company shall include on any registration statement filed with the SEC, all shares issuable
upon exercise of this Warrant. Failure to do so will result in liquidated damages of $50,000, being immediately due and payable
to the Investor at its election in the form of cash payment.

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be duly executed as of the Issuance Date set forth above.

 

	 	DATA443
    RISK MITIGATION, INC.
	 	 
	 	 
	 	TRITON
    FUNDS LP

 

    	9

     

    

 

EXHIBIT
A

 

EXERCISE
NOTICE

 

(To
be executed by the registered holder to exercise this Common Stock Purchase Warrant)

 

The
Undersigned holder hereby exercises the right
to purchase _________________ of the shares of Common Stock (“Warrant Shares”) of DATA443 RISK MITIGATION, INC., a
Nevada corporation (the “Company”), evidenced by the attached copy of the Common Stock Purchase Warrant (the “Warrant”).
Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant.

 

	1.	Form
                                                         of Exercise Price. The Investor intends that payment of the Exercise Price shall be made as (check one):

 

	 	[  ]	a cash exercise
    with respect to _________________ Warrant Shares; or
	 	[  ]	by cashless exercise
    pursuant to the Warrant.

 

	2.	Payment
of Exercise Price. If cash exercise is selected above, the holder shall pay the applicable Aggregate Exercise Price in the
sum of $___________________ to the Company in accordance with the terms of the Warrant.

 

	3.	Delivery
                                                         of Warrant Shares. The Company shall deliver to the holder __________________ Warrant Shares in accordance with the terms
                                                         of the Warrant.

 

Date: _______________

 

	(Print
Name of Registered Holder) 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 

 

    	10

     

    

 

EXHIBIT
B

 

ASSIGNMENT
OF WARRANT

 

(To
be signed only upon authorized transfer of the Warrant)

 

For
Value Received, the undersigned hereby sells,
assigns, and transfers unto ____________________ the right to purchase _______________ shares of common stock of DATA443 RISK
MITIGATION, INC. to which the within Common Stock Purchase Warrant relates and appoints ____________________, as attorney-in-fact,
to transfer said right on the books of DATA443 RISK MITIGATION, INCORPORATED. with full power of substitution and re-substitution
in the premises. By accepting such transfer, the transferee has agreed to be bound in all respects by the terms and conditions
of the within Warrant.

 

Date: ____________

 

	 	 
	(Signature) *	 
	 	 
	 	 
	(Name)	 
	 	 
	 	 
	(Address)	 
	 	 
	 	 
	(Social Security or Tax Identification No.)	 

 

*
The signature on this Assignment of Warrant must correspond to the name as written upon the face of the Common Stock Purchase
Warrant in every particular without alteration or enlargement or any change whatsoever. When signing on behalf of a corporation,
partnership, trust or other entity, please indicate your position(s) and title(s) with such entity.

 

    	11Exhibit
10.1

 

COMMON
STOCK PURCHASE AGREEMENT

 

This
Common Stock Purchase Agreement (the “Agreement”), dated as of December 10, 2020 (the “Execution Date”),
is entered into by and between Data443 Risk Mitigation, Inc., a Nevada corporation (the “Company”), and Triton Funds
LP, a Delaware limited partnership (the “Investor”).

 

RECITAL

 

WHEREAS,
upon the terms and subject to the conditions contained herein, the Investor agrees to purchase, and the Company agrees to sell,
up to One Million Dollars ($1,000,000) of common stock, par value $0.001 per share (the “Common Stock”), of the Company,
the resales of which shares of Common Stock shall be registered under the Securities Act of 1933, as amended (“1933 Act”)
pursuant to an effective Registration Statement on Form S-1.

 

NOW
THEREFORE, in consideration of the foregoing recital, which shall be considered an integral part of this Agreement, the covenants
and agreements set forth hereafter, and other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the Company and the Investor hereby agree as follows:

 

AGREEMENT

 

SECTION
I

DEFINITIONS

 

For
all purposes of and under this Agreement, the following terms shall have the respective meanings below, and such meanings shall
be equally applicable to the singular and plural forms of such defined terms.

 

“1934
Act” shall mean the Securities Exchange Act of 1934, as amended, or any similar federal statute, and the rules and regulations
of the SEC thereunder, all as the same will then be in effect.

 

“Administrative
Fee” shall mean $5,000 payable by the Company to the Investor upon execution of this Common Stock Purchase Agreement and
$10,000 from the Initial Closing.

 

“Business
Day” shall mean any day on which the Principal Market for the Purchased Shares is open for trading from the hours of 9:30
am until 4:00 pm eastern time.

 

“Closing”
shall mean the date that is no later than five (5) Business Days after the Purchase Notice Date.

 

“Commitment
Period” shall mean the period beginning on the Business Day immediately following the Execution Date and ending on the expiration
of this Agreement.

 

“Minimum
Closing Price” shall mean the closing price of the Common Stock that is equal to or greater than $0.009.

 

“Principal
Market” shall mean the New York Stock Exchange, the NYSE Amex, the Nasdaq Capital Market, the Nasdaq Global Market, the
Nasdaq Global Select Market or the OTC Markets, whichever is the market on which the Common Stock is listed.

 

“Purchase
Notice” shall mean the written notice sent to the Investor by the Company, which Purchase Notice shall state the total amount
of Purchased Shares that the Company intends to sell to the Investor pursuant to the terms of this Agreement based on the formula
set forth in Section 2.1 hereof.

 

“Purchased
Shares” shall mean shares of Common Stock issued pursuant to the terms of this Agreement.

 

“Investment
Amount” shall mean the total dollar amount to be sold by the Company at a Closing, not to exceed Five Hundred Thousand Dollars
($500,000).

 

“Registration
Statement” means the Registration Statement on Form S-1 to be filed with the SEC registering the Purchased Shares issuable
hereunder.

 

“SEC”
shall mean the U.S. Securities and Exchange Commission.

 

SECTION
II

PURCHASE
AND SALE OF COMMON STOCK

 

2.1
PURCHASE AND SALE OF PURCHASED SHARES. Subject to the terms and conditions set forth herein, the Company shall sell to
the Investor, and the Investor shall purchase from the Company, that number of Purchased Shares equal to the Investment Amount.
The Investment Amount shall be calculated based on the total number of Purchased Shares set forth in the Purchase Notice delivered
to Investor as more particularly set forth in Section 2.2 below, multiplied by $0.006.

 

2.2
DELIVERY OF PURCHASE NOTICE. Subject to the terms and conditions herein, the Company may deliver the Purchase Notice to
the Investor during the Commitment Period setting forth the total number of Purchased Shares to be purchased by Investor, which
Purchase Notice shall be in the form attached hereto as Exhibit A and incorporated herein by reference. During the Commitment
Period, the Company shall not submit a Purchase Notice until the previous Closing has been completed. No Purchase Notice will
be made in an amount less than twenty-five thousand dollars ($25,000) or greater than five hundred thousand dollars ($500,000).

 

    	 

     

    

 

2.3
CONDITIONS TO INVESTOR’S OBLIGATIONS. Notwithstanding anything to the contrary in this Agreement, the Investor shall
not be obligated to purchase any Purchased Shares at the Closing unless each of the following conditions are satisfied:

 

	 	(i)	the
    Registration Statement shall remain effective and available for sale of the Purchased Shares at all times until the Closing;
	 	 	 
	 	(ii)	at
    the Closing, the Common Stock shall have been listed or quoted for trading on the Principal Market and shall not have been
    suspended from trading, at any time, after the Execution Date and the Company shall not have been notified of any pending
    or threatened proceeding or other action to suspend the trading of the Common Stock;
	 	 	 
	 	(iii)	no
    injunction shall have been issued and remain in force, or action commenced by a governmental authority which has not been
    stayed or abandoned, prohibiting the purchase or the issuance of the Purchased Shares; and
	 	 	 
	 	(iv)	the
    issuance of the Purchased Shares will not violate any requirements of the Principal Market.
	 	 	 
	 	(v)	Minimum
    Closing Price is met on the date Investor receives the Purchase Notice Shares as DWAC Shares by custodian. 

 

If
any of the events described in clauses (i) through (v) above occurs prior to the Closing, then the Investor shall have no obligation
to purchase the Purchased Shares set forth in the Purchase Notice.

 

2.4
MECHANICS OF PURCHASE OF PURCHASED SHARES BY INVESTOR. The Closing of the purchase of the Purchased Shares set forth in
the Purchase Notice shall occur no later than five (5) Business Days following the receipt by Investor’s custodian of the
Purchased Shares (the “Purchase Notice Date”); it being understood that the Investor shall deliver the Purchase Notice
to Investor’s custodian on the Purchase Notice Date. The Purchase Notice Date shall be deemed delivered (i) on the day it
is delivered to Investor on a Business Day prior to 9:30 am eastern time; (ii) if it is delivered on a day other than a Business
Day or on a Business Day after 9:30 am eastern time, it shall be on the day that is the next subsequent Business Day. The Investor
shall deliver the Investment Amount by wire transfer of immediately available funds to an account designated by the Company set
forth in the Purchase Notice. In addition, on or prior to the Closing, each of the Company and Investor shall deliver to each
other all documents, instruments and writings required to be delivered or reasonably requested by either of them pursuant to this
Agreement in order to implement and effect the transactions contemplated herein.

 

2.5
LIMITATION ON AMOUNT OF OWNERSHIP. Notwithstanding anything to the contrary in this Agreement, in no event shall the Investor
be entitled to purchase that number of Purchased Shares, which when added to the sum of the number of shares of Common Stock beneficially
owned (as such term is defined under Section 13(d) and Rule 13d-3 of the 1934 Act), by the Investor, would exceed 9.99% of the
number of shares of Common Stock outstanding on the Purchase Notice Date, as determined in accordance with Rule 13d-1(j) of the
1934 Act.

 

SECTION
III

INVESTOR’S
REPRESENTATIONS, WARRANTIES AND COVENANTS

 

By
executing this Agreement, the Investor represents, warrants and agrees that:

 

3.1
POWER AND AUTHORITY. The undersigned has full power and authority to act on behalf of and bind the Investor to its obligations
as set forth herein and making these representations, warranties and agreements.

 

3.2
EFFECTIVE REGISTRATION STATEMENT. The Purchased Shares are being offered pursuant to the Registration Statement and Investor
is solely relying on the Registration Statement and all periodic filings made by the Company under the 1934 Act (“SEC Filings”),
in determining whether to purchase the Purchased Shares.

 

3.3
REVIEW OF SEC FILINGS. Investor has had full opportunity to read and review the Registration Statement, the documents incorporated
therein by reference, and consult with an attorney regarding such Registration Statement.

 

3.4
ACCURACY OF REPRESENTATIONS. The information provided herein and these representations, warranties and agreements are accurate
and complete, and shall remain so until the undersigned notifies the Company otherwise.

 

    	 

     

    

 

SECTION
IV

REPRESENTATIONS
AND WARRANTIES OF THE COMPANY

 

Except
as disclosed on the Company’s SEC Filings, the Company represents and warrants to the Investor that:

 

4.1
ORGANIZATION AND QUALIFICATION. The Company is a corporation duly organized and validly existing in good standing under
the laws of the State of Nevada and has the requisite corporate power and authorization to own its properties and to carry on
its business as now being conducted. Both the Company and the companies it owns or controls (“Subsidiaries”) are duly
qualified to do business and are in good standing in every jurisdiction in which its ownership of property or the nature of the
business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in
good standing would not have a Material Adverse Effect. As used in this Agreement, “Material Adverse Effect” means
a change, event, circumstance, effect or state of facts that has had or is reasonably likely to have, a material adverse effect
on the business, properties, assets, operations, results of operations, financial condition or prospects of the Company and its
Subsidiaries, if any, taken as a whole, or on the transactions contemplated hereby or by the agreements and instruments to be
entered into in connection herewith, or on the authority or ability of the Company to perform its obligations under the Agreement.

 

4.2
AUTHORIZATION; ENFORCEMENT; COMPLIANCE WITH OTHER INSTRUMENTS.

 

	 	(i)	The
    Company has the requisite corporate power and authority to enter into the Agreement and to issue the Purchased Shares in accordance
    with the terms hereof and thereof.
	 	 	 
	 	(ii)	The
    execution and delivery of the Agreement by the Company and the consummation by it of the transactions contemplated hereby
    and thereby, including without limitation the issuance of the Purchased Shares pursuant to this Agreement, have been duly
    and validly authorized by the Company’s Board of Directors and no further consent or authorization is required by the
    Company, its Board of Directors, or its shareholders.
	 	 	 
	 	(iii)	The
    Agreements have been duly and validly executed and delivered by the Company.
	 	 	 
	 	(iv)	The
    Agreements constitute the valid and binding obligations of the Company enforceable against the Company in accordance with
    their terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency,
    reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’
    rights and remedies.

 

4.3
ISSUANCE OF SHARES. The Company has reserved the amount of Purchased Shares included in the Registration Statement for
issuance pursuant to the Agreement, which have been duly authorized and reserved (subject to adjustment pursuant to the Company’s
covenant set forth in Section 5.5 below) pursuant to this Agreement. Upon issuance in accordance with this Agreement, the
Purchased Shares will be validly issued, fully paid for and non-assessable and free from all taxes, liens and charges with respect
to the issuance thereof. In the event the Company cannot register a sufficient number of Purchased Shares for issuance pursuant
to this Agreement, the Company will use its best efforts to authorize and reserve for issuance the number of Purchased Shares
required for the Company to perform its obligations hereunder as soon as reasonably practicable.

 

4.4
INSURANCE. Each of the Company’s Subsidiaries are insured by insurers of recognized financial responsibility against
such losses and risks and in such amounts as management of the Company reasonably believes to be prudent and customary in the
businesses in which the Company and its Subsidiaries are engaged. Neither the Company nor any of its Subsidiaries has been refused
any insurance coverage sought or applied for and neither the Company nor its Subsidiaries has any reason to believe that it will
not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect.

 

4.5
DILUTIVE EFFECT. The Company’s executive officers and directors have studied and fully understand the nature of the
transactions contemplated by this Agreement and recognize that the issuance of the Purchased Shares will have a dilutive effect
on the shareholders of the Company. The Board of Directors of the Company has concluded, in its good faith business judgment,
and with full understanding of the implications, that such issuance is in the best interests of the Company. The Company specifically
acknowledges that, subject to such limitations as are expressly set forth in the Agreement, its obligation to issue shares of
Common Stock pursuant to this Agreement is absolute and unconditional regardless of the dilutive effect that such issuance may
have on the ownership interests of other shareholders of the Company.

 

SECTION
V

COVENANTS
OF THE COMPANY

 

5.1
BEST EFFORTS. The Company shall use all commercially reasonable efforts to timely satisfy each of the conditions set forth
in this Agreement.

 

5.2
REPORTING STATUS. Until one of the following occurs, the Company shall file all reports required to be filed with the SEC
pursuant to the 1934 Act, and the Company shall not terminate its status, or take an action or fail to take any action, which
would terminate its status as a reporting company under the 1934 Act: (i) this Agreement terminates pursuant to Section 8
and the Investor has the right to sell all of the Purchased Shares, or (ii) the date on which the Investor has sold all the Purchased
Shares.

 

5.3
USE OF PROCEEDS. The Company will use the proceeds from the sale of the Purchased Shares for general corporate and working
capital purposes and acquisitions or assets, businesses or operations or for other purposes that the Board of Directors, in good
faith deem to be in the best interest of the Company.

 

5.4
FINANCIAL INFORMATION. During the Commitment Period, the Company agrees to make available to the Investor via EDGAR or
other electronic means the following documents and information on the forms set forth: (i) its Annual Reports on Form 10-K, its
Quarterly Reports on Form 10-Q, any Current Reports on Form 8-K and any Registration Statements or amendments filed pursuant to
the 1933 Act; (ii) copies of any notices and other information made available or given to the shareholders of the Company generally,
contemporaneously with the making available or giving thereof to the shareholders; and (iii) within two (2) calendar days of filing
or delivery thereof, copies of all documents filed with, and all correspondence sent to, the Principal Market, any securities
exchange or market, or the Financial Industry Regulatory Association, unless such information is material nonpublic information.

 

    	 

     

    

 

5.5
RESERVATION OF PURCHASED SHARES. The Company shall take all action necessary to at all times have authorized and reserved
the amount of Purchased Shares included in the Registration Statement for issuance pursuant to the Agreement. In the event that
the Company determines that it does not have a sufficient number of authorized shares of Common Stock to reserve and keep available
for issuance as described, the Company shall use all commercially reasonable efforts to increase the number of authorized shares
of Common Stock by seeking shareholder approval for the authorization of such additional shares.

 

5.6
LISTING. The Company shall maintain the listing of all of the Purchased Shares on the Principal Market and each other national
securities exchange and automated quotation system, if any, upon which shares of Common Stock are then listed (subject to official
notice of issuance) and shall maintain, such listing of all Purchased Shares issuable under the terms of the Agreement. Neither
the Company nor any of its Subsidiaries shall take any action which would be reasonably expected to result in the delisting or
suspension of the Common Stock on the Principal Market (excluding suspensions of not more than one (1) Business Day resulting
from business announcements by the Company). The Company shall promptly provide to the Investor copies of any notices it receives
from the Principal Market regarding the continued eligibility of the Common Stock for listing on such automated quotation system
or securities exchange. The Company shall pay all fees and expenses in connection with satisfying its obligations under this Section
5.6.

 

5.7
CORPORATE EXISTENCE. The Company shall use all commercially reasonable efforts to preserve and continue the corporate existence
of the Company.

 

5.8
NOTICE OF CERTAIN EVENTS AFFECTING REGISTRATION. The Company shall promptly notify the Investor upon the occurrence of
any of the following events in respect of a Registration Statement or related prospectus in respect of an offering of the Purchased
Shares: (i) receipt of any request for additional information by the SEC or any other federal or state governmental authority
during the period of effectiveness of the Registration Statement for amendments or supplements to the Registration Statement or
related prospectus; (ii) the issuance by the SEC or any other federal or state governmental authority of any stop order suspending
the effectiveness of any Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt of any notification
with respect to the suspension of the qualification or exemption from qualification of any of the Purchased Shares for sale in
any jurisdiction or the initiation or notice of any proceeding for such purpose; (iv) the happening of any event that makes any
statement made in such Registration Statement or related prospectus or any document incorporated or deemed to be incorporated
therein by reference untrue in any material respect or that requires the making of any changes in the Registration Statement,
related prospectus or documents so that, in the case of a Registration Statement, it will not contain any untrue statement of
a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not
misleading, and that in the case of the related prospectus, it will not contain any untrue statement of a material fact or omit
to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading; and (v) the Company’s reasonable determination that a post-effective amendment
or supplement to the Registration Statement would be appropriate, and the Company shall promptly make available to Investor any
such supplement or amendment to the related prospectus.

 

5.9
TRANSFER AGENT. The Company shall deliver instructions to its transfer agent to issue Purchased Shares to the Investor
that are issued to the Investor pursuant to the Agreement.

 

5.10
ACKNOWLEDGEMENT OF TERMS. The Company hereby represents and warrants to the Investor that: (i) it is voluntarily entering
into this Agreement of its own free will, (ii) it is not entering this Agreement under economic duress, (iii) the terms of this
Agreement are reasonable and fair to the Company, and (iv) the Company has had independent legal counsel of its own choosing review
this Agreement, advise the Company with respect to this Agreement, and represent the Company in connection with this Agreement.

 

SECTION
VI

EXPIRATION

 

This
Agreement shall expire upon the earlier to occur of:

 

6.1
that date when the Investor has purchased an aggregate of One Million Dollars ($1,000,000) in Purchased Shares pursuant to this
Agreement; or

 

6.2
June 30, 2021.

 

Any
and all Purchased Shares issuable to Investor, or penalties or other amounts, if any, due under this Agreement shall be immediately
payable and due Investor upon expiration of this Agreement.

 

SECTION
VII

INDEMNIFICATION

 

In
consideration of the parties mutual obligations set forth in the Agreement, the Company (the “Indemnitor”) shall defend,
protect, indemnify and hold harmless the Investor and all of the investor’s shareholders, officers, directors, employees,
counsel, and direct or indirect investors and any of the foregoing person’s agents or other representatives (including,
without limitation, those retained in connection with the transactions contemplated by this Agreement) (collectively, the “Indemnitees”)
from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages,
and reasonable expenses in connection therewith (irrespective of whether any such Indemnitee is a party to the action for which
indemnification hereunder is sought), and including reasonable attorneys’ fees and disbursements (the “Indemnified
Liabilities”), incurred by any Indemnitee as a result of, or arising out of, or relating to (I) any misrepresentation or
breach of any representation or warranty made by the Indemnitor or any other certificate, instrument or document contemplated
hereby or thereby; (II) any breach of any covenant, agreement or obligation of the Indemnitor contained in the Agreement or any
other certificate, instrument or document contemplated hereby or thereby; or (III) any cause of action, suit or claim brought
or made against such Indemnitee by a third party and arising out of or resulting from the execution, delivery, performance or
enforcement of the Agreement or any other certificate, instrument or document contemplated hereby or thereby, except insofar as
any such misrepresentation, breach or any untrue statement, alleged untrue statement, omission or alleged omission is made in
reliance upon and in conformity with information furnished to Indemnitor which is specifically intended for use in the preparation
of any such Registration Statement, preliminary prospectus, prospectus or amendments to the prospectus. To the extent that the
foregoing undertaking by the Indemnitor may be unenforceable for any reason, the Indemnitor shall make the maximum contribution
to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable law. The indemnity
provisions contained herein shall be in addition to any cause of action or similar rights Indemnitor may have, and any liabilities
the Indemnitor or the Indemnitees may be subject to.

 

    	 

     

    

 

SECTION
VIII

GOVERNING
LAW; DISPUTES SUBMITTED TO ARBITRATION

 

8.1
LAW GOVERNING THIS AGREEMENT. This Agreement shall be governed by and construed in accordance with the laws of the State
of Nevada without regard to principles of conflicts of laws. Any action brought by either party against the other concerning the
transactions contemplated by this Agreement shall be brought only in the state or federal courts located in Los Angeles, California.
The parties to this Agreement hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder
and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. The parties executing
this Agreement and other agreements referred to herein or delivered in connection herewith on behalf of the Company agree to submit
to the in personam jurisdiction of such courts and hereby irrevocably waive trial by jury. The prevailing party shall be entitled
to recover from the other party its reasonable attorney’s fees and costs. In the event that any provision of this Agreement
or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law,
then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform
with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the
validity or enforceability of any other provision of any agreement. Each party hereby irrevocably waives personal service of process
and consents to process being served in any suit, action or proceeding in connection with this Agreement by mailing a copy thereof
via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for
notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law.

 

8.2
LEGAL FEES; AND MISCELLANEOUS FEES. Except as otherwise set forth in the Agreement, including but not limited to the Administrative
Fee, each party shall pay the fees and expenses of its advisers, counsel, the accountants and other experts, if any, and all other
expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement.
Any attorneys’ fees and expenses incurred by either the Company or the Investor in connection with the preparation, negotiation,
execution and delivery of any amendments to this Agreement or relating to the enforcement of the rights of any party, after the
occurrence of any breach of the terms of this Agreement by another party or any default by another party in respect of the transactions
contemplated hereunder, shall be paid on demand by the party which breached this Agreement and/or defaulted, as the case may be.
The Company shall pay all stamp and other taxes and duties levied in connection with the issuance of any Purchased Shares.

 

8.3
SURVIVAL. The representations and warranties of the Company and the Investor contained in this Agreement shall survive
the Closing and expiration of this Agreement.

 

8.4
ENTIRE AGREEMENT; AMENDMENTS. This Agreement is the FINAL AGREEMENT between the Company and the Investor with respect to
the terms and conditions set forth herein, and, the terms of this Agreement may not be contradicted by evidence of prior, contemporaneous,
or subsequent oral agreements of the Parties. No provision of this Agreement may be amended other than by an instrument in writing
signed by the Company and the Investor, and no provision hereof may be waived other than by an instrument in writing signed by
the party against whom enforcement is sought.

 

8.5
SEVERABILITY. If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity
or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or
the validity or enforceability of any provision of this Agreement in any other jurisdiction.

 

8.6
PRICING OF COMMON STOCK. For purposes of this Agreement, the price of the Common Stock shall be determined by the formula
set forth in Section 2.1 hereof.

 

SECTION
IX

NON-DISCLOSURE
OF NON-PUBLIC INFORMATION

 

The
Company shall not disclose non-public information to the Investor.

 

Your
signature on this Signature Page evidences your agreement to be bound by the terms and conditions of this Agreement as of the
date first written above. The undersigned signatory hereby certifies that he has read and understands this Agreement, and the
representations made by the undersigned in this Agreement are true and accurate and agrees to be bound by its terms.

 

	TRITON
    FUNDS LP	 
	 	 
	By:
    	 	 
	Name:	Ashkan
    Mapar	 
	Title:	Authorized
    Signatory	 
	 	 	 
	DATA443
    RISK MITIGATION, INC. 	 
	 	 	 
	By:	 	 
	Name:	Jason
    Remillard	 
	Title:	Chief
    Executive Officer 	 

 

    	 

     

    

 

EXHIBIT
A

 

PURCHASE
NOTICE

 

Date:
_____, 202_

 

TRITON
FUNDS LP,

 

This
is to inform you that as of today the Company hereby elects to exercise its right pursuant to this Agreement to require you to
purchase _____ Purchased Shares for an Investment Amount not to exceed Five Hundred Thousand Dollars ($500,000). The Company’s
wire instructions are as follows:

 

[Insert
Wire Instructions]

 

The
total Investment Amount and price per Purchased Shares shall be calculated in accordance with the terms and conditions set forth
in Section 2.1 of the Agreement.

 

Regards,

 

	DATA443
RISK MITIGATION, INC.	 
	 	 
	By:	 	 
	Name:	Jason
    Remillard	 
	Title:	Chief
    Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}]]